Tenderwize
Retour à la recherche

Accord de remise sur le ranibizumab

AOK Niedersachsen. Die Gesundheitskasse.·Hannover, Germany·Deadline Oct 27, 2027 · 340 days left·Open·Supplies·Framework
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Ranibizumab (ATC-Code: S01LA04).

55/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

55 / 100

Complexité

66 / 100

Facteurs de risque

No contract value, purchase volume, minimum commitment, or expected demand is stated in the provided data.

AOK Niedersachsen may replace the open-house agreements with exclusive rebate contracts, and the open-house contracts m...

No procurement documents available

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Informations clés

Pouvoir adjudicateur
AOK Niedersachsen. Die Gesundheitskasse.
Pays
Allemagne
CPV
33600000 - Pharmaceutical products
Date limite
Oct 27, 2027

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Dec 2027
  • Supply of pharmaceutical products containing ranibizumab (ATC S01LA04) under a non-exclusive rebate agreement with AOK Niedersachsen.
  • Open-house participation by pharmaceutical undertakings or qualifying groups, with identical contract terms and generally no individual negotiations.
Afficher le résumé complet

Open-house framework arrangement for non-exclusive pharmaceutical rebate contracts concerning ranibizumab (ATC S01LA04) with AOK Niedersachsen in Germany. Eligible pharmaceutical undertakings or qualifying groups may join on identical, non-negotiable terms without a selection decision. Contracts may start monthly during the period, but all end by 31 December 2027 and may terminate earlier if exclusive contracts enter into force. Contract value, detailed contractual terms, and required submission documents are not provided in the analyzed notice data.

Risques

No contract value, purchase volume, minimum commitment, or expected demand is stated in the provided data.

AOK Niedersachsen may replace the open-house agreements with exclusive rebate contracts, and the open-house contracts m...

No procurement documents available

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • The arrangement is non-exclusive and may be replaced during its term by exclusive rebate contracts.
  • Contracts may be terminated with six weeks' notice to the end of a month.

Administrative

  • All contracts end no later than 31 December 2027, regardless of the contract signature date.

Critères d'attribution

Lot 1

Price is identified as the award criterion, but no description or weighting is provided. The open-house model states that no selection decision will be made.

Acheteur

Localisation

Hannover, DEU

Identifiant

AOK- Niedersachsen. Die Gesundheitskasse

Activité

Health

Lots (1)

LOT-0000

Ranibizumab pharmaceutical rebate agreement

Non-exclusive rebate agreement under Section 130a(8) SGB V for medicines containing ranibizumab (ATC S01LA04), operated under an open-house model. The information is derived from the structured notice and TED XML notice; the underlying contract documents were not provided for analysis.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE929, Germany

Durée

Dec 2025 - Dec 2027

Catégorie

Pharmaceutical products

Critères d'attribution

Price

Date limite

Deadline Oct 27, 2027

Détails de la procédure

Date de publication
10 Nov 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
746904-2025

Appels d'offres similaires

Cookies & Privacy

With your consent, we use Google Analytics, Microsoft Clarity (session recordings) and Google Ads cookies to understand how Tenderwize is used and to measure our advertising. You can change your choice at any time via “Cookie Settings” in the footer. Cookie Policy · Privacy Policy